Alzheimer’s drug development halted following toxic reaction: industry news round-up

Written by Sharon Salt, Editor

In this week’s industry news round-up we set the focus on updates from the US FDA, as well as the halt of an Alzheimer’s drug following reports of a toxic reaction. Find out more below about our selection of the highlights this week: Our pick of the headlines include: Acorda Therapeutics announced FDA extension of Inbrija™ review FDA approves AJOVY™ for the preventive treatment of migraine Allergan and Sosei halt global development for Alzheimer’s drug following toxic reaction Acorda Therapeutics announced FDA extension of Inbrija™ review Acorda Therapeutics (NY, USA) has announced that the FDA has extended the Prescription Drug...

To view the full article, please register now for access

It's completely free